: 02772 222 684TERLIS
FOR I.V. USE 1mg/10 ml
SINGLE USE AMPOULE
COMPOSITION:
Each ml contains:
Terlipressin ( As Acetate) 100 mcg.
Water for Injection I.P. q.s.
DESCRIPTION:
Terlis (Terlipressin )is the synthetic, long-acting analogue of vasopressin. Chemically, Terlipressin is N-glycylglycylglycyl vasopressin. The molecular is C52h74N15O15S2and molecular weight is 1227.39.
STRUCTURAL FORMULA:
Its structural formula is :
Gly-Gly-Gly-Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Lys-GlyNH2
DESCRIPTION OF INJECTION:
Terlis is clear colourless solution filled in 10ml clear glass ampoule.
ACTIONS:
Terlipressin may be regarded as a circulating depot of lysine vasopressin. Following intravenous injection, three glycylmoieties are enzymatically cleaved from the N-terminus to releaxe lysine vasopressin.
Terlipressin has significant vasoconstrictive and anti hemorrhagic effect. The most significant change is reduced blood flow in splanchnic area with following reduced blood flow in splanchnic area with following reduction of hepatic blood flow and portal blood pressure. Pharmacodynamic studies have shown that like other similar peptides, terlipressin causes intraarteriolar, intravenous and intravenular constrictions primarily in splanchnic area as well as constriction of oesophageal unstrapped muscles and increase in tonus and intestinal peristaltic activity.
In addition to its vasopressor effects, terlipressin stimulates myometrial activity, even in non pregnant uterus.
The anti-shock effect of terlipressin has been confirmed not only for haemorrhagic but also for endotoxic and histaminic shocks. There are no clinical manifestations of the antidiuretic effect of terlipressin.
PHARMACOKINETICS :
Terlipressin as such is inactive in relation to smooth muscle but it serves as a chemical depot for active pharmacological substances formed by enzymatic cleavage process. Copared with lysine-vasopressin, the effect comes more slowly, however much longer.
Lysine-vasopressin is subject to usual biodegradation in liver, kidneys and other tissues. The intravenous pharmacological profile can be described using a two-compartment model. The excretion half-life is about 40 minutes, metabolic clearance about 9 ml/kg x min and distribution volume about 0.5 l/kg.
Estimated lysine-vasopressin concentration can be found in plasma, 30 minutes after administration of terlipressin with peak values after 60-120 minutes.
INDICATIONS :
Bleeding in gastrointestinal and urogential systems such as esophageal varies, gastric and duodenal ulcerations, functional and similar types of metrorrhagia and in case of miscarriage or abortion and similar situation.
Bleeding occurred as a result of operation, in particular those in the abdominal and pelvic area.
Local application in gynecological operations, such as cervix porta uteri.
Hepatorenal syndrome.
DOSAGE AND ADMINISTRATION:
Administration :
Terlis must only be administered intravenously.
Dosage :
Bleeding Oesophageal Varices:
Adults :
Initial bolus dose 2 mg should be administered by an intravenous bolus injection over one minute, followed by 1 mg – 2 mg every 4 – 6 hours for nex 24 -48 hours. For prevention of bleeding recurrence, continued medication shall be recommended, until the bleeding has been controlled. The dose shall be administered I.V.( as a rule bolus ) injection or short-tern infusion.
Children :
8 to 20 mcg/kg of body weight given at intervals of 4 – 8 hours.
Other types of gastrointestinal hemorrhagic :
- mg (1000 mcg ) every 4 – 6 hours can be used as first aid medication in cases of clinically suspected bleeding in upper part of gastrointestinal system.
Bleeding from the splanchnic region in children :
The usual dose ranges from 8 to 20 mcg/kg of body weight given at intervals of 4 – 8 hours. The administration of the dosage should be continued throughout the period of bleeding. The general dose recommendation is as in cases of bleeding in adults. For sclerotized oesophageal varices a single dose of 20 mcg/kg body weight is given in bolus form.
Bleeding from the urogenital tract :
The dosage will range 0.2 – 1.0 mg (200-1000 ɯg) every4- 6 hours.
Juvenile Metrorrhagia :
For juvenile metrorrhagia, doses of 5 – 20 ɯg/kg of body weight are recommended. The administration should be intravenous.
Local application in gynecological operations:
Add saline to 0.4 mg ( 400 mcg ) dose to obtain 10 ml and apply intracervically or paracervically. The effects of such preparation can be seen after approximately 5-10 minutes. If necessary, increase or repeat the dose.
Hepatorenal syndrome :
1-2 mg twice daily as I.V.bolus for 2-4 weeks. Dose may e adjusted if required.
CONTRAINDICATIONS:
- First trimester of pregnancy
- Septic shock
WARNINGS :
In 2nd and 3rd trimester of pregnancies, the benefits against risk of administration always should be considered.
Caution is advised when administering to elderly patients with ischemia, serious hypertension, cardiac arrhythmia or asthma bronchiole.
When administering Terlis especially in higher doses (0.8 mg = 800 ɯg and more), tight monitoring of blood pressure, heart rate and liquid balance is recommended. This is specially for patients with hypertension, heart insufficiency and elderly patients.
Terlis is not a replacement of blood substitution in patients with blood volume deficit. Regarding individual cases of local necrosts, reported after administration of terlipressin, an intramuscular administration of 0.5 mg (500mcg) doses and more should be avoided. Intravenous administration is increasingly preferred.
PRECAUTIONS
Pregnancy:
Terlipressin causes rise in myometrial activity and decrease in uteral blood flow. Reproduction studies in rabbits and rats with higher doses showed increased abortion rate embryo deaths. In infantslower birth weight as well as increased anomaly rate has been found. Terlipressin is contraindicated in pregnancy.
Lactation:
Terlipressin distribution in breast milk is not available; however significant absorption of unchanged peptides in gastrointestinal system of child seems not be probable. There is no definite data on terlipressin use in lactating women.
Paediatric use :
There is very limited clinical experience in children, caution to be exercised during use in this group of patients.
Geriatric use :
There is very limited clinical experience in elderly, caution to be exercised during use in this group of patients.
INTERACTIONS :
Both oxytocin and methylergometrine increase the vasoconstrictive and uterotonic effects. Terlipressin enhances the hypotensive effect of non-selective blockers in the portal vein. Concomitant medications with substances lowering heart rate can result in serious bradycardia.
INCOMPATIBILITIES :
Not known.
SIDE EFFECTS :
The most frequent effects in course of administration are: paleness, hypertension, abdominal pain, accelerated defecation or abdominal colics, nausea, diarrhea and headache. In less frequent cases bradycardia has been reported. Serious adverse effects are rare. Individual cases of heart attack, heart failure, dyspnoea and local necrosis at injection place were also reported.
OVERDOSAGE :
The recommended dose (2 mg/4 hour ) should not be exceeded since an exceeded dose increases the risk of serious effects on the systemic circulation.
TREATMENT OF OVERDOSAGE :
Increase in blood pressure in patients with known hypertension has beencontrolled with clonidine 150mg I.V. Severe bradycardia should be treated with atropine.
PHARMACEUTICAL PRECAUTIONS :
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
STORATE :
Store at temperature between 2°C to 8°C protect from light and frost.
PRESENTATION :
One ampoule of 10 ml is packed in carton with insert.
Manufactured & Marketed by:
FIDULIS BIO INC.
At: Dhandha, Idar Road, Himatnagar 383001
A subsidiary o f
FIDULIS BIO PTY LTD
Level 1, 139, Macquarie St, Sydney, NSW 2000, PO Box R1784.
Royal Exchange NSW 1225, Australia
Ph: 02 42951789